Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menis, Silvia Novello, Emilio Bria

Research output: Contribution to journalArticlepeer-review


Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

Original languageEnglish
Pages (from-to)78-88
Number of pages11
JournalLung Cancer
Issue number1
Publication statusPublished - Jul 2011


  • Adjuvant chemotherapy
  • Non-small cell lung cancer
  • Postoperative radiotherapy
  • Survey

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)'. Together they form a unique fingerprint.

Cite this